Ogen .625
Drug - Ogen .625
The trade name of the product as shown on the labeling.
Dosage -
TABLET; ORAL
The product dosage form and route separated by a semi-colon.
Active Ingredient(s) -
Estropipate
Multiple ingredients are in alphabetical order.
Strength -
0.75MG
The potency of the active ingredient(s), Estropipate. May repeat for multiple part products.
Applicant -
PHARMACIA AND UPJOHN
The firm name holding legal responsibility for Ogen .625. The firm name is condensed to a maximum twenty character unique string.
New Drug Application (NDA) Number -
083220
The FDA assigned number to Ogen .625. Format is nnnnnn.
Product Number -
001
The FDA assigned number to identify Ogen .625. Each strength is a separate product. May repeat for multiple part products. Format is nnn.
Therapeutic Equivalence (TE) Code -
AB
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.
Approval Date -
Approved Prior to Jan 1, 1982
The date Ogen .625 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".
Reference Listed Drug (RLD) -
No
The pioneer or innovator of Ogen .625. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.
Type -
RX
The group or category of approved drugs Ogen .625 is in. Format is RX, OTC, DISCN.
Applicant Full Name -
Pharmacia And Upjohn Co
The full name of the firm holding legal responsibility for the new application of Ogen .625.
Ogen .625
|
